TORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- On September 11, 2020, Health Canada approved Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who ...

Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine. A common ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes (T2D ...

The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial. The Food and Drug Administration (FDA) has approved 2 additional dosage strengths of Trulicity ® ...

Mounjaro (tirzepatide) and Trulicity (dulaglutide) are prescription medications that help manage blood sugar levels in adults with type 2 diabetes. Though they work in slightly different ways, they ...

KNOXVILLE, Tenn. (WATE) — It’s hard to watch TV these days without seeing an article or ad praising weight-loss wonder drugs. Some of these drugs, like Trulicity, are approved to treat type 2 diabetes ...

WeightWatchers' stock soared Tuesday after the company said it is getting into the prescription drug weight loss business with the acquisition of Sequence. Sequence is a telehealth provider that ...

Eli Lilly is in prime position with its new GIP/GLP-1 launch tirzepatide and its entrenched diabetes blockbuster Trulicity. Chalk it up to a temporary shortage of its chief rival Novo Nordisk’s ...

Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to review a new dosing regimen over the need for more ...